## C. V. Prof. Andrew R. Gennery

**Appointments** 

01/2020 to date Sir James Spence Professor of Child Health

06/2018 to date Professor/Honorary Consultant in Paediatric Immunology & Haematopoeitic Stem

Cell Transplantation, Instute of Cellular Medicine, Newcastle University

08/2009 – 05/2018 Watson Reader/Honorary Consultant in Paediatric Immunology & Haematopoeitic

Stem Cell Transplantation, Instute of Cellular Medicine, Newcastle University

11/2002 - 07/2009 Watson Clinical Senior Lecturer/Honorary Consultant in Paediatric Immunology &

Bone Marrow Transplantation, Instute of Cellular Medicine, Newcastle University

## Panel / Committee / Board Membership and Advisory Roles

2019 to date CIBMTR Co-Chair of Primary Immune Deficiencies, Inborn Errors of Metabolism

and other NMMD Working Committee

2017 to 2020 Chair, ERN-RITA Guidelines Working Party

2019 to date Member, Blood and Marrow Transplantation (BMT) Clinical Reference Group

2008 to date Human Tissue Authority Designated Individual – Newcastle upon Tyne

Foundation Hospital Trust Therapeutic Tissue Bank

2008 to date Member of the British Committee for Standards in Haematology Blood

Transfusion Task Force formulating Guidelines on the use of irradiated blood

products

Dr Gennery is Professor in Paediatric Immunology and Haematopoietic Stem Cell Transplantation at the University of Newcastle upon Tyne and Honorary Consultant for the Northern Supra-Regional Bone Marrow Transplant Unit for SCID and related disorders, at the Great North Children's Hospital, Newcastle upon Tyne, clinically qualified and active. He spent a year of post-doctoral studies working with Anne Durandy and Alain Fischer in the Necker Hospital in Paris and was involved in the discovery of Cytidine Deaminase one of the first genes to be discovered involved in class switch recombination and somatic hypermutation.

He has been a consultant in Newcastle for 18 years. His research interests include immunoreconstitution following haematopoietic stem cell transplant for primary immunodeficiency, long-term outcomes of transplantation for primary immunodeficiency (and in particular Chronic Granulomatous Disease and Severe Combined Immunodeficiency), DNA repair disorders and their appropriate treatment and Di George Syndrome. More recently, he has adapted new methods of T cell depletion for patients with primary immunodeficiency, and established extracorporeal photopheresis for the treatment of children with graft versus host disease. He has discovered important mechanistic insights relating to the action of extracorporeal photopheresis. He is exploring the use of defibrotide for treatment of non-VOD endothelial cell activation disorders post-HSCT.

He is a member of ESID and EBMT, recently chaired the ESID/EBMT Inborn Errors Working Party group and the ESID Clinical Working Party and ERN-RITA Guidelines Working Party and is currently Co-chair of CIBMTR Primary Immune Deficiencies, Inborn Errors of Metabolism and other NMMD Working Committee. He has published over 340 papers on primary immunodeficiency, has co-authored important multi-centre publications on the outcomes of cohorts of children with rare primary immunodeficiencies following HSCT, and contributed to relevant chapters in several major textbooks. He has co-authored national guidelines for the use of irradiated blood products in patients with primary immunodeficiency in the UK, guidelines on the management of children with 22q11 deletion syndrome and guidelines for the use of extracorporeal photopheresis for the treatment of acute graft versus host disease. He has written international guidelines for the treatment of patients with DNA repair disorders and CD40 ligand deficiency.